ANP Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$57,582.16
Insider Selling (Last 12 Months): A$0.00

Antisense Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antisense Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antisense Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for ANP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Antisense Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/28/2022Mark DiamondInsiderBuy244,687A$0.11A$26,915.57
12/22/2021Mark DiamondInsiderIssued470,549A$0.24A$112,931.76
11/8/2021Charmaine GittlesonInsiderBuy133,333A$0.23A$30,666.59
12/3/2020Robert MosesInsiderIssued90,201A$0.10A$9,020.10
12/23/2019Graham MitchellInsiderIssued7,000,000A$0.09A$609,000.00
12/20/2019Robert MosesInsiderBuy100,000A$0.09A$8,800.00
12/18/2019Graham MitchellInsiderExercise48,036A$0.08A$3,842.88
12/16/2019Robert MosesInsiderBuy618,888A$0.08A$49,511.04
12/3/2019Robert MosesInsiderBuy800,000A$0.08A$64,000.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Antisense Therapeutics (ASX:ANP)

Antisense Therapeutics logo
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Read More on Antisense Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


1,318,309 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Antisense Therapeutics?

Antisense Therapeutics' top insider shareholders include:
  1. Charmaine Gittleson (Insider)
  2. Mark Diamond (Insider)
  3. Robert Moses (Insider)
Learn More about top insider investors at Antisense Therapeutics.